A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

Clinical trial NCT04103905 · COMPLETED

Trial details

NCT number: NCT04103905
Sponsor: Beijing Mabworks Biotech Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

CD20-positive B Cell Non-Hodgkin Lymphoma

Start date: 2017-02-10
Primary completion: 2019-05-30
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.